English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

This study aimed to analyze maternal serum  β -arrestin-1 and  β -arrestin-2 concentrations in pregnant women complicated with gestational diabetes mellitus (GDM) and compare them with the normoglycemic uncomplicated healthy control group. A prospective case-control study was conducted, including pregnant women complicated with GDM between 15 February 2021, and 31 July 2021. We recorded serum  β -arrestin-1 and  β -arrestin-2 concentrations of the participants. Receiver operating characteristic (ROC) curves were used to describe and compare the performance of diagnostics value of variables  β -arrestin-1, and  β -arrestin-2. The mean  β -arrestin-1 and  β -arrestin-2 levels were found to be significantly lower in the GDM group (41.0 ± 62.8 ng/mL, and 6.3 ± 9.9 ng/mL) than in the control group (93.1 ± 155.4 ng/mL, and 12.4 ± 17.7, respectively,  p  &lt; .001). When we analyze the area under the ROC curve (AUC), maternal serum  β -arrestin-1 and  β -arrestin-2 levels can be considered a statistically significant parameter for diagnosing GDM.  β -arrestin-1 had a significant negative correlation with fasting glucose ( r  = −0.551,  p  &lt; .001), plasma insulin levels ( r  = −0.522,  p  &lt; .001), HOMA-IR ( r  = −0.566,  p  &lt; .001), and HbA1C ( r  = −0.465,  p  &lt; .001).  β -arrestin-2 was significantly negatively correlated with fasting glucose ( r  = −0.537,  p  &lt; .001), plasma insulin levels ( r  = −0.515,  p  &lt; .001), HOMA-IR ( r  = −0.550,  p  &lt; .001), and HbA1C ( r  = −0.479,  p  &lt; .001). β -arrestin 1 and  β -arrestin 2 could be utilized as biomarkers in the diagnosis of GDM. The novel therapeutic strategies targeting these  β -arrestins may be designed for the GDM treatment.

The reduced serum concentrations of β -arrestin-1 and β -arrestin-2 in pregnancies complicated with gestational diabetes mellitus